Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiffany Chang

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Blood|December 21, 2023
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trialSteven W Pipe, Peter Collins, Christophe Dhalluin, et al.
Innovations in Clinical Neuroscience|September 27, 2024
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic ReviewWaguih William IsHak, Ashley Meyer, Luiza Freire, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Pediatric Blood & Cancer|July 17, 2015
Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective StudyDeepak Chellapandian, Furqan Shaikh, Cor van den Bos, et al.
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Molecular Biology and Evolution|August 4, 2009
Roles of trans and cis variation in yeast intraspecies evolution of gene expressionHuang-Mo Sung, Tzi-Yuan Wang, Daryi Wang, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
The New England Journal of Medicine|November 17, 2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia ALindsey A George, Paul E Monahan, M Elaine Eyster, et al.
Breast Cancer Research and Treatment|July 1, 2021
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cellsMargarite D Matossian, Steven Elliott, T Van Hoang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 11, 2012
Iatrogenic Exserohilum infection of the central nervous system: mycological identification and histopathological findingsW Robert Bell, Justin B Dalton, Chad M McCall, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Blood|December 21, 2023
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trialSteven W Pipe, Peter Collins, Christophe Dhalluin, et al.
Innovations in Clinical Neuroscience|September 27, 2024
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic ReviewWaguih William IsHak, Ashley Meyer, Luiza Freire, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Pediatric Blood & Cancer|July 17, 2015
Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective StudyDeepak Chellapandian, Furqan Shaikh, Cor van den Bos, et al.
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Molecular Biology and Evolution|August 4, 2009
Roles of trans and cis variation in yeast intraspecies evolution of gene expressionHuang-Mo Sung, Tzi-Yuan Wang, Daryi Wang, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
The New England Journal of Medicine|November 17, 2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia ALindsey A George, Paul E Monahan, M Elaine Eyster, et al.
Breast Cancer Research and Treatment|July 1, 2021
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cellsMargarite D Matossian, Steven Elliott, T Van Hoang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 11, 2012
Iatrogenic Exserohilum infection of the central nervous system: mycological identification and histopathological findingsW Robert Bell, Justin B Dalton, Chad M McCall, et al.
Pageof 8